China Drug Price Negotiations: Another Race To The Bottom？
Competition, Coverage and Cost Control
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?
You may also be interested in...
From general economic policies around common prosperity and 'dual circulation' to its 'COVID Zero' approach, the Chinese Communist Party’s once-in-five-years National Congress will chart the country’s direction as challenges mount, growth stalls and consumption plunges.
China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.
Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.